Literature DB >> 2956200

Regional cardioprotection by subselective intracoronary nifedipine is not due to enhanced collateral flow during coronary angioplasty.

G Pop, P W Serruys, F Piscione, P J de Feyter, M van den Brand, T Huizer, J W de Jong, P G Hugenholtz.   

Abstract

Twelve patients with proximal stenosis of the left anterior descending artery, normal myocardial wall motion but without angiographically demonstrable collateral circulation, were studied during transluminal occlusion. Prior to the first transluminal occlusion before crossing the lesion with the balloon, patients were randomly given 0.2 mg nifedipine or its solvent in the left mainstem. The same dose was repeated via the balloon catheter, positioned across the lesion, immediately prior to the second transluminal occlusion. In all patients great cardiac venous flow and ST-elevation were monitored during and after each transluminal occlusion. The lactate extraction ratio A-GCV/A (A = arterial, GCV = great cardiac vein) was determined prior to the angioplasty procedure, 10-15 seconds after each transluminal occlusion and 10 minutes after the third transluminal occlusion. Great cardiac venous flow rose significantly to an average of 160% of basal flow when nifedipine was administered into the mainstem before the angioplasty procedure while its solvent had no effect. During each transluminal occlusion, great cardiac venous flow diminished on average by 30% in those who received nifedipine and by 28% in those who received only its solvent. This difference was statistically not significant. After angioplasty great cardiac venous flow was slightly, but not significantly, increased in both groups with respect to basal flow (104% resp. 120% of control). Patients who received nifedipine in the post-stenotic area just before the second transluminal occlusion, had significantly lower lactate production, measured immediately after the transluminal occlusion compared with the patients who received only its solvent (P less than 0.01). The ST-elevation during the second transluminal occlusion was significantly lower in the nifedipine group (0.1 mm in nifedipine group versus 1.4 mm in solvent group; P less than 0.05, unpaired t-test). Nifedipine given intracoronary in the post-stenotic area just before coronary angioplasty reduces lactate release and electrocardiographic signs of myocardial ischemic injury. This regional cardioprotective effect seems not due to an enhanced collateral flow, but to a regional cardioplegic effect, which precedes the ischemic event.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2956200     DOI: 10.1016/0167-5273(87)90267-1

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Protective effects of pretreatment with intracoronary nifedipine on myocardial ischemia and dysfunction.

Authors:  I Amende; G Herrmann; R Simon; W P Hood; P Wenzlaff; P R Lichtlen
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Similar antiischemic effects of intracoronary atenolol and nifedipine during brief coronary occlusions in humans.

Authors:  S Ghio; S De Servi; L Angoli; E Bramucci; E Eleuteri; S Raffaghello; G Specchia
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

3.  Effect of gallopamil on myocardial ischaemia during percutaneous transluminal coronary angioplasty.

Authors:  B Rauch; J Neumann; G Richardt; R Kranzhöfer; R Barth; R Zimmermann; H P Koch; H Tillmanns; A Schömig
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  Effect of amlodipine on myocardial functional and metabolic recovery following coronary occlusion and reperfusion in dogs.

Authors:  G J Gross; N E Farber; G M Pieper
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

5.  Intracoronary nisoldipine: effects on acute myocardial ischemia during coronary angioplasty.

Authors:  I Amende; G Herrmann; R Simon; P Wenzlaff; P R Lichtlen
Journal:  Cardiovasc Drugs Ther       Date:  1989-01       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.